Comparison of the effect of ticagrelor and clopidogrel on platelet functions and inflammation factor in ;patients with acute coronary syndrome after PCI
10.3760/cma.j.issn.1008-6706.2017.03.030
- VernacularTitle:替格瑞洛与氯吡格雷对急性冠脉综合征患者经皮冠状动脉介入治疗术后血小板功能和炎性因子的影响比较
- Author:
Mingying LI
- Keywords:
Coronary artery disease;
Ticagrelor;
Blood platelets;
Chemokines
- From:
Chinese Journal of Primary Medicine and Pharmacy
2017;24(3):439-442,443
- CountryChina
- Language:Chinese
-
Abstract:
Objective To compare the effect of ticagrelor and clopidogrel on platelet functions and inflamma-tion factor in patients with acute coronary syndrome(ACS)after PCI.Methods 180 patients with ACS who taken PCI were chosen and randomly divided into the observation group and the control group(90 cases in each group).All patients of the two groups were given conventional treatment,and the control group received clopidogrel treatment on the basis of routine therapy preoperation and postoperation,while the observation group received clopidogrel treatment on the basis of the control group treatment.Before treatment and 24 h,7 d,28 d after treatment,the C-reactive protein (CRP),interleukin 6(IL-6),tumor necrosis factor alpha(TNF-α),myeloperoxidase(MPO),soluble CD40 receptor (sCD40L),platelet maximum aggregation rate(MPAR)and P2Y12 response unit(PRU)in the two groups were recorded and compared,as well as the main cerebrovascular events after six months follow-up.Results In the two groups before treatment,MPAR and PRU had no statistically significant differences(t=0.41,0.19,all P>0.05). 24h,7d and 28d after operation,MPAR and PRU were significantly decreased compared with before treatment(t≥2.09,all P<0.05).MPAR in the observation group were (53.24 ±11.20)%,(42.33 ±10.80)%,(30.77 ± 8.99)% respectively,which were significantly lower than those in the control group[(57.34 ±13.21)%,(48.09 ± 10.90)%,(38.87 ±8.97)%](t=2.24,3.56,6.05,all P<0.05).24h,7d and 28d after operation,PRU in the observation group were (214.56 ±13.45)U,(190.57 ±12.21)U,(113.26 ±10.90)U respectively,which were significantly lower than those in the control group[(225.59 ±14.78)U,(210.21 ±14.09)U,(143.23 ±12.01)U] (t=5.24,2.11,17.53,all P<0.05).In the two groups before treatment,CRP CD40L,IL-6 and TNF-αhad no statistically significant differences(all P>0.05 ).24h after treatment,CRP,sCD40L,IL-6 and TNF-αin the two groups all significantly increased(all P<0.05),and then decreased.24h,7d,28d after treatment,DCRP,sCD40L,IL-6 and TNF-αin the observation group were all significantly lower than those in the control group (t=60.79, 50.30,27.95,12.98,40.29,16.73,15.03,7.30,all P<0.05).And,the incidence rate of cardiovascular adverse events of the observation group was 2.22%,which was significantly lower than 10.00% of the control group(χ2 =5.714,P<0.05).Conclusion Compared with clopidogrel,using ticagrelor to treat ACS patients after PCI has better antiplatelet aggregation and inflammation effects,which can reduce the incidence of cardiovascular adverse events.
